Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30821996 | 1.00 | HSD17B10 (0.49) | HSD17B10KDM4EALDH1A1CA12CA1 | |
| SCHEMBL10068933 | 0.93 | KMO (0.51) | HSD17B10KDM4EALDH1A1CA12CA1 | |
| SCHEMBL184149 | 0.93 | HSD17B10 (0.54) | HSD17B10KDM4EALDH1A1CA12CA1 | |
| SCHEMBL10068703 | 0.92 | KMO (0.54) | HSD17B10KDM4EALDH1A1CA12CA1 | |
| SCHEMBL4389273 | 0.91 | CA12 (0.52) | HSD17B10KDM4EALDH1A1CA12CA1 | |
| SCHEMBL10068936 | 0.86 | HSD17B10 (0.51) | HSD17B10KDM4EALDH1A1CA12CA1 | |
| SCHEMBL184302 | 0.85 | KMO (0.53) | HSD17B10KDM4EALDH1A1CA12CA1 | |
| SCHEMBL8619431 | 0.84 | HSD17B10 (0.50) | HSD17B10KDM4EALDH1A1CA12CA1 | |
| SCHEMBL4392929 | 0.83 | KMO (0.55) | HSD17B10KDM4EALDH1A1CA12CA1 | |
| SCHEMBL9121827 | 0.83 | CA12 (0.60) | HSD17B10KDM4EALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326777-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH BEIJING BIOPHARMA TECH CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| CN-102958912-B | Benzohydrol derivatives, a preparation process and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2015-01-14 | — | — | CN | disclosed |
| CN-102112445-B | Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors | BRISTOL MYERS SQUIBB CO | 2014-06-18 | — | — | CN | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| CN-102958912-A | Benzohydrol derivatives, a preparation process and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2013-03-06 | — | — | CN | disclosed |
| CN-102372653-A | Diphenyl methanol derivative, preparation method thereof and application of diphenyl methanol derivative in medicine | JIANGSU HENGRUI MEDICINE CO | 2012-03-14 | — | — | CN | disclosed |
| WO-2012019428-A1 | BENZOHYDROL DERIVATIVES, A PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
| EP-2297103-B1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| CN-102112445-A | Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors | BRISTOL MYERS SQUIBB CO | 2011-06-29 | — | — | CN | disclosed |
| EP-2297103-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| CN-101687864-A | 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors | ASTRAZENECA AB | 2010-03-31 | — | — | CN | disclosed |
| WO-2009152082-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326777-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | MRGPRX4, MRGPRX1, MRGPRX2 | HSD17B10 2546/4885KDM4E 2213/4885ALDH1A1 1047/4885 |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | HSD17B10 920/4885KDM4E 3403/4885ALDH1A1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.